Conference Paper: Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleFactors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
AuthorsO'Suilleabhain, CB1
Poon, RTP1
Yong, JL1
Ooi, GC1
Tso, WK1
Fan, ST1
Issue Date2003
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
CitationBritish Journal Of Surgery, 2003, v. 90 n. 3, p. 325-331 [How to Cite?]
DOI: http://dx.doi.org/10.1002/bjs.4045
AbstractBackground: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear. Methods: Pretreatment variables were analysed for factors predictive of actual 5-year survival from a prospective database of patients with inoperable HCC treated by TACE between 1989 and 1996. Results: Complete 5-year follow-up (median 91 months) was obtained for 320 patients who underwent a median of 4 (range 1-41) TACEs. Median tumour size was 9 (range 1-28) cm. There were 25 5-year survivors (8 per cent), including eight with tumours larger than 10 cm in diameter and three with portal vein branch involvement. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count below 150 × 109 per litre (P = 0.011), albumin concentration greater than 35 g/l (P = 0.04), α-fetoprotein level below 1000 ng/ml (P = 0.007), unilobar tumour (P = 0.027), fewer than three tumours (P = 0.015), absence of venous invasion (P = 0.011), and tumour diameter less than 8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin concentration greater than 35 g/l (P = 0.011), unilobar tumour (P = 0.012) and α-fetoprotein level below 1000 ng/ml (P = 0.014) were independent prognostic factors on multivariate analysis. Conclusion: Five-year survival is possible with TACE for inoperable HCC, even in some patients with advanced tumours. Unilobar tumours, α-fetoprotein level below 1000 ng/ml and albumin concentration greater than 35 g/l were factors predictive of 5-year survival.
ISSN0007-1323
2011 Impact Factor: 4.606
2011 SCImago Journal Rankings: 0.335
DOIhttp://dx.doi.org/10.1002/bjs.4045
ISI Accession Number IDWOS:000182437600010
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorO'Suilleabhain, CB
dc.contributor.authorPoon, RTP
dc.contributor.authorYong, JL
dc.contributor.authorOoi, GC
dc.contributor.authorTso, WK
dc.contributor.authorFan, ST
dc.date.accessioned2010-09-06T08:39:20Z
dc.date.available2010-09-06T08:39:20Z
dc.date.issued2003
dc.description.abstractBackground: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear. Methods: Pretreatment variables were analysed for factors predictive of actual 5-year survival from a prospective database of patients with inoperable HCC treated by TACE between 1989 and 1996. Results: Complete 5-year follow-up (median 91 months) was obtained for 320 patients who underwent a median of 4 (range 1-41) TACEs. Median tumour size was 9 (range 1-28) cm. There were 25 5-year survivors (8 per cent), including eight with tumours larger than 10 cm in diameter and three with portal vein branch involvement. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count below 150 × 109 per litre (P = 0.011), albumin concentration greater than 35 g/l (P = 0.04), α-fetoprotein level below 1000 ng/ml (P = 0.007), unilobar tumour (P = 0.027), fewer than three tumours (P = 0.015), absence of venous invasion (P = 0.011), and tumour diameter less than 8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin concentration greater than 35 g/l (P = 0.011), unilobar tumour (P = 0.012) and α-fetoprotein level below 1000 ng/ml (P = 0.014) were independent prognostic factors on multivariate analysis. Conclusion: Five-year survival is possible with TACE for inoperable HCC, even in some patients with advanced tumours. Unilobar tumours, α-fetoprotein level below 1000 ng/ml and albumin concentration greater than 35 g/l were factors predictive of 5-year survival.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationBritish Journal Of Surgery, 2003, v. 90 n. 3, p. 325-331 [How to Cite?]
DOI: http://dx.doi.org/10.1002/bjs.4045
dc.identifier.doihttp://dx.doi.org/10.1002/bjs.4045
dc.identifier.epage331
dc.identifier.hkuros77825
dc.identifier.isiWOS:000182437600010
dc.identifier.issn0007-1323
2011 Impact Factor: 4.606
2011 SCImago Journal Rankings: 0.335
dc.identifier.issue3
dc.identifier.openurl
dc.identifier.pmid12594668
dc.identifier.scopuseid_2-s2.0-0037339179
dc.identifier.spage325
dc.identifier.urihttp://hdl.handle.net/10722/83296
dc.identifier.volume90
dc.languageeng
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
dc.publisher.placeUnited Kingdom
dc.relation.ispartofBritish Journal of Surgery
dc.relation.referencesReferences in Scopus
dc.rightsBritish Journal of Surgery. Copyright © John Wiley & Sons Ltd.
dc.titleFactors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
dc.typeConference_Paper
Author Affiliations
  1. The University of Hong Kong